2026-05-11 Posted by TideChem view:113
In endocrine research and translational biopharmaceutical development, modulating the growth hormone / insulin-like growth factor 1 (GH/IGF-1) axis requires a precise balance between molecular stability and physiological mimicry. Native human growth hormone-releasing hormone, or hGHRH(1-29), possesses potent secretagogue activity but suffers from an exceptionally short plasma half-life, typically under 7 minutes. This rapid clearance is driven by the proteolytic enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal dipeptide, rendering the molecule inactive.
To overcome this structural vulnerability, medicinal chemists developed CJC-1295 without DAC, universally known in academic literature as Modified GRF 1-29 (Mod GRF 1-29). This synthetic peptide represents a highly optimized 29-amino-acid analog engineered to resist enzymatic hydrolysis while preserving the natural, pulsatile signaling cascade of endogenous GHRH.
Crucially, researchers must distinguish this compound from its sister molecule, CJC-1295 with DAC (Drug Affinity Complex). The absence of the affinity complex entirely alters the molecule's pharmacokinetic profile, transforming it from a long-acting steady-state stimulant into a precision tool for simulating natural endocrine rhythms.
CJC-1295 without DAC is a fully synthetic peptide variant derived from the functional core of human GHRH. The native sequence is selectively altered by substituting four specific amino acids at critical points of enzymatic vulnerability: Tyr-1 to D-Ala at position 2, Ala-8 to Asp at position 8, Gly-15 to Ala at position 15, and Met-27 to Leu at position 27.
The substitution of D-alanine at the second position alters the steric presentation of the N-terminal cleavage site, effectively blocking the catalytic binding of DPP-4. The remaining substitutions enhance structural stability, prevent chemical oxidation at the methionine residue, and preserve alpha-helical structural integrity during storage and systemic transport.
Unlike the DAC-modified variant, which includes a 30th amino acid coupled to a maleimidopropionic acid linker, Modified GRF 1-29 lacks any reactive functional groups designed for serum albumin conjugation. Following subcutaneous administration, the peptide does not form covalent bonds with circulating proteins.
Consequently, its clearance is governed by standard renal filtration and secondary endopeptidase pathways, resulting in a distinct plasma half-life of approximately 30 minutes. While this is significantly longer than wild-type GHRH, it avoids the persistent, days-long systemic exposure characteristic of albumin-bound formulations.
Modified GRF 1-29 acts as a highly selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein coupled receptor (GPCR) predominantly expressed on the surface of somatotroph cells in the anterior pituitary gland. The binding kinetics of the modified peptide trigger a canonical intracellular signaling cascade:
Receptor activation induces a conformational shift that exchanges GDP for GTP on the G-alpha-s subunit.
The activated G-alpha-s subunit stimulates transmembrane adenylyl cyclase, driving a rapid rise in intracellular cyclic adenosine monophosphate (cAMP) levels.
Elevated cAMP binds to the regulatory subunits of Protein Kinase A (PKA), releasing active catalytic subunits.
PKA phosphorylates the cAMP response element-binding (CREB) protein and opens voltage-gated calcium channels, promoting an influx of extracellular calcium.
This coordinated cascade drives the transcription of growth hormone mRNA and triggers the immediate exocytosis of pre-formed GH storage vesicles into the systemic circulation.
Because CJC-1295 without DAC clears rapidly from the bloodstream, this receptor activation occurs in a brief, controlled window. This kinetic profile mirrors the physiological pulses of endogenous GHRH, allowing somatotroph cells to restore intracellular hormone pools and reset receptor sensitivity between exposures. This episodic clearance avoids the receptor down-regulation, clathrin-mediated endocytosis, and systemic insulin resistance often caused by continuous, non-pulsatile GHRH receptor hyperstimulation.
To design accurate in vivo and in vitro protocols, preclinical research teams must carefully evaluate the contrasting pharmacological properties of these two variants:
Mod GRF 1-29 contains a streamlined 29-amino-acid sequence with a free C-terminus, minimizing steric bulk. In contrast, CJC-1295 with DAC features a 30-amino-acid core terminated with a maleimide group that binds permanently to endogenous albumin.
The free peptide variant exhibits a terminal half-life of roughly 30 minutes, necessitating frequent administration to maintain target effects. The DAC-modified version exploits albumin recycling pathways, extending its half-life to between 6 and 8 days.
Mod GRF 1-29 induces distinct, transient growth hormone spikes that return to baseline within hours, preserving natural circadian rhythms. The DAC variant creates a sustained, elevated baseline of both GH and IGF-1, eliminating natural pulsatile variance.
Modified GRF 1-29 is the ideal selection for studies investigating sleep-cycle interactions, metabolic pulse-amplitude modulation, and synergistic combination therapies. The DAC variant is preferred for models requiring long-term chronic GH elevation or low-frequency dosage compliance testing.
In academic endocrinology laboratories, Modified GRF 1-29 serves as a reliable probe to evaluate the negative feedback loops governing the somatotropic axis. Researchers utilize the peptide to investigate how circulating somatostatin levels or elevated free fatty acids modulate pituitary responsiveness, helping to uncover the mechanisms behind metabolic conditions like obesity-induced GH suppression.
A major focus in biopharmaceutical R&D is the co-administration of Modified GRF 1-29 with growth hormone-releasing peptides (GHRPs) or small-molecule ghrelin mimetics, such as Ipamorelin or GHRP-2. GHRH analogs and GHRPs activate distinct, complementary receptor systems (GHRHR and GHS-R1a, respectively).
When administered together, they produce a synergistic effect: GHRH drives the initial cAMP-mediated secretion cascade, while the ghrelin mimetic suppresses hypothalamic somatostatin release and amplifies the intracellular calcium response. Preclinical trials evaluating these combinations generate foundational data for therapeutics targeting cachexia, sarcopenia, and age-related muscle atrophy.
To prevent experimental error and ensure chemical stability during long-term protocols, research technicians should implement strict handling workflows:
Reconstitution and Solution Longevity: Lyophilized peptide preparations should be reconstituted using sterile bacteriostatic water containing 0.9% benzyl alcohol to inhibit microbial growth. Reconstituted solutions must be stored at 2 to 8 degrees Celsius and used within 28 days to minimize gradual peptide hydrolysis.
Chromatographic Purity Verification: Prior to initiating animal treatments, custom-synthesized lots must undergo validation via High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (LC-MS). Ensuring a minimum purity threshold of 98% prevents trace peptide fragments from causing off-target artifacts or confounding immunogenic responses.
In Vivo Timing Parameters: To optimize the growth hormone secretory response in animal models, injections should be scheduled around fasting windows—typically 30 minutes before a meal or 90 minutes post-feeding. Free fatty acids and glucose elevations stimulate hypothalamic somatostatin secretion, which can blunt the GHRHR-mediated response.
CJC-1295 without DAC remains an essential tool in endocrinology and peptide drug design due to its combination of DPP-4 resistance and short-acting, physiological clearance. While long-acting formulations have distinct utility in chronic deficiency models, the ability of Modified GRF 1-29 to stimulate natural, pulsatile growth hormone secretion makes it invaluable for studying metabolic homeostasis, tissue repair, and synergistic receptor crosstalk. By maintaining strict control over reconstitution parameters, purity verification, and dosing schedules, researchers can leverage this analog to drive reproducible advancements in peptide therapeutics.